SOUTH PLAINFIELD, N.J., Oct. 29, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ending September 30, 2019.
The Friedreich ataxia program continues to advance with an IND submission now expected in mid-2020.
Wednesday, October 30, 2019
Symposium updates Friedreich’s ataxia community on advances against FA
Written by Anne DeLotto Baier · October 29, 2019 @ 12:55 pm · Filed under Hot News, Morsani College of Medicine, Neurosciences & Brain Repair, Patient Care, Research, School of Biomedical Sciences.
Less than three weeks after the 10th annual Friedreich’s Ataxia (FA) Scientific Symposium at USF, Reata Pharmaceuticals Inc. announced that its MOXIe trial of daily therapy with omaveloxolone capsules (RTA 408) improved the neurological function of patients with FA – a rare, debilitating and life-shortening neuromuscular disorder.
Less than three weeks after the 10th annual Friedreich’s Ataxia (FA) Scientific Symposium at USF, Reata Pharmaceuticals Inc. announced that its MOXIe trial of daily therapy with omaveloxolone capsules (RTA 408) improved the neurological function of patients with FA – a rare, debilitating and life-shortening neuromuscular disorder.
Subscribe to:
Posts (Atom)
